PMID- 24737951
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140624
LR  - 20211021
IS  - 1477-3163 (Print)
IS  - 1477-3163 (Electronic)
IS  - 1477-3163 (Linking)
VI  - 13
DP  - 2014
TI  - Targeted therapy for renal cell carcinoma: The next lap.
PG  - 3
LID - 10.4103/1477-3163.127638 [doi]
LID - 3
AB  - Advances in rationally targeted therapeutics over the last decade have 
      transformed the clinical care of advanced kidney cancer. While oncologists 
      consolidate the gains of the wave of new agents, comprising a panoply of 
      anti-vascular endothelial growth factor multi-targeted tyrosine kinase inhibitors 
      and inhibitors of the mammalian target of rapamycin (mTOR), there is an 
      increasing sense that a plateau has been reached in the short term. It is 
      sobering that all currently approved targeted therapies have not yielded durable 
      remissions and remain palliative in intent. In the context of recent insights in 
      kidney cancer biology, we review promising ongoing and future approaches for 
      kidney cancer therapeutics aimed toward forging new paths in the systemic 
      management of renal cell carcinoma. Broadly, candidate agents for such innovative 
      strategies include immune check-point inhibitors, anti-cancer stem cell agents, 
      next-generation anti-vascular endothelial growth factor receptor and anti-mTOR 
      agents as well as more investigational agents in the preclinical and early 
      clinical development settings.
FAU - Kanesvaran, Ravindran
AU  - Kanesvaran R
AD  - Department of Medical Oncology, National Cancer Centre Singapore, Singapore 
      169610, Republic of Singapore.
FAU - Tan, Min-Han
AU  - Tan MH
AD  - Department of Medical Oncology, National Cancer Centre Singapore, Singapore 
      169610, Republic of Singapore ; Institute of Bioengineering and Nanotechnology, 
      Singapore 138669, Republic of Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140220
PL  - India
TA  - J Carcinog
JT  - Journal of carcinogenesis
JID - 101153623
PMC - PMC3986548
OTO - NOTNLM
OT  - Immunotherapy
OT  - renal cell carcinoma
OT  - targeted therapy
OT  - tyrosine kinase inhibitors
COIS- Conflict of Interest: R. K. is an advisory board member for Glaxo-Smith-Kline. M. 
      H. T. has filed patents for predictive biomarkers for kidney cancer.
EDAT- 2014/04/17 06:00
MHDA- 2014/04/17 06:01
PMCR- 2014/02/20
CRDT- 2014/04/17 06:00
PHST- 2013/10/14 00:00 [received]
PHST- 2013/12/15 00:00 [accepted]
PHST- 2014/04/17 06:00 [entrez]
PHST- 2014/04/17 06:00 [pubmed]
PHST- 2014/04/17 06:01 [medline]
PHST- 2014/02/20 00:00 [pmc-release]
AID - JC-13-3 [pii]
AID - 10.4103/1477-3163.127638 [doi]
PST - epublish
SO  - J Carcinog. 2014 Feb 20;13:3. doi: 10.4103/1477-3163.127638. eCollection 2014.